The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.

Attention deficit hyperactivity disorder (ADHD)

Date

Company

Partner

Deal terms

March 2009

GlaxoSmithKline

Shire

co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US

November 2008

GlaxoSmithKline

Paladin Labs

three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada

Perrigo Company (US) has appointed Ellen Hoffing as a new director. Ms Hoffing has served as president and chief executive officer of the development-stage biopharmaceutical company Applied NeuroSolutions since 2006.

Panacea Pharmaceuticals is developing products to detect and treat CNS diseases and cancer.